Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

BWAY vs ECOR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BWAY Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 8–2 Matrix Metrics)

BWAY Overall Winner 6-Pillar Tally: BWAY 5 – 0 ECOR (1 Tie) Matrix Metrics: BWAY 8 – 2 ECOR

As of Nov 19, 2026, Brainsway Ltd. (BWAY) is the stronger overall head-to-head candidate over electroCore, Inc. (ECOR) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BWAY carries a Unified Composite Score of 32.4/100 (SELL) at $8.73 (17.4x Forward P/E, 12.5% operating margin), whereas ECOR carries 56.8/100 (HOLD) at $4.85 (N/M Forward P/E, -33.1% operating margin).

  • Composite vs. Pillar Nuance: While ECOR currently prints a higher short-term Unified Composite Score (56.8/100 HOLD vs. BWAY 32.4/100 SELL), BWAY captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (12.5% vs. -33.1% operating margin) and revenue trajectory (+35.4% vs. +11.5% YoY).
  • Technical & Structure Timing Caution: BWAY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.0); meanwhile ECOR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BWAY vs ECOR
BWAY NASDAQ Head-to-Head Winner
Brainsway Ltd. American Depositary Shares
Surgical & Medical Instruments & Apparatus
$8.73
-2.78% 1D
Market Cap $361.5M
TTM Revenue $108M
Forward P/E 17.4x
Beta / 30D Vol 1.92β · 67% Vol
Unified Composite Score
32.4 / 100 SELL
Tech 25.0 Fund 47.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -11.8%), weak momentum, RSI 29
RSI-14: 29.0 · SMA20: $10.70 · SMA50: $11.85
ECOR NASDAQ
electroCore, Inc. Common Stock
Electromedical & Electrotherapeutic Apparatus
$4.85
-6.19% 1D
Market Cap $47.7M
TTM Revenue $38M
Forward P/E N/M
Beta / 30D Vol 1.52β · 155% Vol
Unified Composite Score
56.8 / 100 HOLD
Tech 68.0 Fund 53.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -11.5%), weak momentum, RSI 32
RSI-14: 31.5 · SMA20: $6.90 · SMA50: $8.67

6-Pillar Scorecard Institutional Category Breakdown (BWAY 5 – 0 ECOR)

Columns: Metric · BWAY · ECOR
1. Valuation Multiples BWAY
Forward P/E 17.4x N/M
Trailing P/E 37.4x N/M
PEG Ratio N/M N/M
EV / Revenue 3.4x 1.4x
2. Growth & Scale BWAY
Revenue Growth (YoY) +35.4% +11.5%
Earnings Growth (YoY) +59.8% +0.0%
TTM Revenue (USD) $108M $38M
Market Cap $361.5M $47.7M
3. Profitability & Quality BWAY
Gross Margin 75.3% 87.7%
Operating Margin 12.5% -33.1%
Net Profit Margin 15.6% -33.5%
Return on Equity (ROE) 12.8% -478.7%
4. Balance Sheet & Cash Flow BWAY
Cash Generation (TTM) $15M EBITDA -$6.9M
Cash Flow Margin 14.0% EBITDA Mgn -18.1%
Net Cash / Leverage $1.97 Book/Sh · 12.8% ROE $4.6M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 111.0% (77th %ile) N/A (N/A)
Put/Call OI Skew Thin ADR Chain N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat BWAY
OpEx & R&D Intensity 62.8% of Rev ($68M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BWAY (8) vs ECOR (2)
Institutional Metric BWAY ECOR Criterion Row Edge
Market Capitalization
Scale
$361.5M $47.7M Larger Scale BWAY
Trailing P/E Ratio
Valuation
37.4x N/M Lower Multiple BWAY
Forward P/E Ratio
Valuation
17.4x N/M Lower Multiple BWAY
Revenue Growth (YoY)
Growth
+35.4% +11.5% Higher Growth BWAY
Operating Margin (TTM)
Profitability
12.5% -33.1% Higher Margin BWAY
Net Profit Margin
Profitability
15.6% -33.5% Higher Margin BWAY
Return on Equity (ROE)
Capital Efficiency
12.8% -478.7% Higher ROE BWAY
52-Week Range Position
Momentum
1% ($9–$27) 6% ($4–$13) Stronger Trend ECOR
Beta / 30D Volatility
Risk Regime
1.92β · 67% Vol 1.52β · 155% Vol Lower Realized Risk BWAY
Unified Institutional Score
Composite Signal
32.4 / 100 (SELL) 56.8 / 100 (HOLD) Higher Composite ECOR
Trailing 12M Revenue (USD)
Operating Scale
$108M $38M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
75.3% 87.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.4x EV/Rev N/M PEG · 1.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$15M EBITDA ($1.97 Book/Sh · 12.8% ROE) -$6.9M ($4.6M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BWAY +6.88 pp
BWAY: -27.13% · ECOR: -34.01%
3M Horizon BWAY +13.13 pp
BWAY: -40.77% · ECOR: -53.9%
6M Horizon ECOR +23.08 pp
BWAY: -42.11% · ECOR: -19.03%
1Y Horizon ECOR +36.97 pp
BWAY: -40.93% · ECOR: -3.96%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BWAY vs ECOR. Trailing 12-month operating profitability (BWAY 12.5% vs ECOR -33.1%) and valuation multiples (BWAY 17.4x vs ECOR N/M Forward P/E) are benchmarked directly in Pillar 4 below.

BWAY ADR TTM Benchmark FX-Normalized USD
TTM Revenue$108M
Gross Margin75.3%
Op. Margin12.5%
ROE / Fwd P/E12.8% · 17.4x
ECOR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$38M
Gross Margin87.7%
Op. Margin-33.1%
ROE / Fwd P/E-478.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BWAY UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 111.0%
IV Percentile 77th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BWAY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ECOR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ECOR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BWAY Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $361.5M market capitalization and 12.5% operating margin.
OpEx & R&D Reinvestment 62.8% of Rev ($68M)
90D Engineering Disclosures 0 Published
ECOR Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $47.7M market capitalization and -33.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BWAY vs ECOR Key Questions & Quantitative Answers

As of Nov 19, 2026, Brainsway Ltd. (BWAY) is the stronger overall head-to-head candidate over electroCore, Inc. (ECOR) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BWAY carries a Unified Composite Score of 32.4/100 (SELL) at $8.73 (17.4x Forward P/E, 12.5% operating margin), whereas ECOR carries 56.8/100 (HOLD) at $4.85 (N/M Forward P/E, -33.1% operating margin). Composite vs. Pillar Nuance: While ECOR currently prints a higher short-term Unified Composite Score (56.8/100 HOLD vs. BWAY 32.4/100 SELL), BWAY captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (12.5% vs. -33.1% operating margin) and revenue trajectory (+35.4% vs. +11.5% YoY). Technical & Structure Timing Caution: BWAY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.0); meanwhile ECOR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BWAY leads the Growth & Scale pillar: BWAY posts +35.4% YoY revenue growth and +59.8% YoY earnings growth on $108M TTM revenue (75.3% gross margin, 12.5% operating margin), compared with ECOR at +11.5% YoY revenue growth and +0.0% YoY earnings growth on $38M TTM revenue (87.7% gross margin, -33.1% operating margin). On trailing 12-month operating scale, BWAY generates $108M in USD-normalized revenue versus $38M for ECOR. In operating R&D and SG&A reinvestment, BWAY deploys 62.8% of Rev ($68M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ECOR.

BWAY screens cheaper on headline valuation multiples. BWAY trades at 17.4x Forward P/E, 37.4x Trailing P/E, N/M PEG, and 3.4x EV/Revenue (14.0% EBITDA margin), whereas ECOR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.4x EV/Revenue (-18.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BWAY (12.8% ROE) versus ECOR (-478.7% ROE) capital efficiency.

In options market volatility and institutional positioning, BWAY carries 111.0% implied volatility (77th %ile, Elevated (60th–80th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.92β · 67% Vol realized risk). By comparison, ECOR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.52β · 155% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.